Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Allogene Therapeutics (ALLO) Return on Assets: 2019-2025

Historic Return on Assets for Allogene Therapeutics (ALLO) over the last 6 years, with Sep 2025 value amounting to -0.46%.

  • Allogene Therapeutics' Return on Assets fell 2.00% to -0.46% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.46%, marking a year-over-year decrease of 2.00%. This contributed to the annual value of -0.43% for FY2024, which is 1.00% up from last year.
  • Per Allogene Therapeutics' latest filing, its Return on Assets stood at -0.46% for Q3 2025, which was up 3.49% from -0.48% recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Return on Assets ranged from a high of -0.17% in Q4 2021 and a low of -0.48% during Q2 2025.
  • Its 3-year average for Return on Assets is -0.45%, with a median of -0.45% in 2024.
  • As far as peak fluctuations go, Allogene Therapeutics' Return on Assets climbed by 10bps in 2021, and later fell by 22bps in 2022.
  • Over the past 5 years, Allogene Therapeutics' Return on Assets (Quarterly) stood at -0.17% in 2021, then decreased by 22bps to -0.39% in 2022, then dropped by 7bps to -0.46% in 2023, then rose by 1bps to -0.45% in 2024, then fell by 2bps to -0.46% in 2025.
  • Its Return on Assets stands at -0.46% for Q3 2025, versus -0.48% for Q2 2025 and -0.47% for Q1 2025.